Cas No.: | 1036969-20-6 |
Chemical Name: | N-[32-[4-[[[[4-[(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)methyl]cyclohexyl]carbonyl]amino]methyl]-1H-1,2,3-triazol-1-yl]-1,5-dioxo-3,9,12,15,18,21,24,27,30-nonaoxa-6-azadotriacont-1-yl]-L-phenylalanyl-N-[4-[[[[[(4S)-4,11-diethyl-3,4,12,14-tetrahydro-9-hydrox |
Synonyms: | CL2-SN-38 |
SMILES: | O=C1N(CC2=C3CC)C(C2=NC4=CC=C(O)C=C34)=CC([C@@](CC)5OC(OCC6=CC=C(NC([C@H](CCCCN)NC([C@@H](NC(COCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCN7C=C(CNC(C8CCC(CN(C9=O)C(C=C9)=O)CC8)=O)N=N7)=O)=O)CC%10=CC=CC=C%10)=O)=O)C=C6)=O)=C1COC5=O |
Formula: | C82H106N12O23 |
M.Wt: | 1627.79 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | CL2-SN-38 is a part of the antibody drug conjugate (ADC), can conjugate with the anti-Trop-2-humanized antibody hRS7. The anti-Trop-2 hRS7-CL2A-SN-38 ADC provides significant and specific antitumor effects against a range of human solid tumor types[1]. |
References: | [1]. Cardillo TM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011 May 15;17(10):3157-69. |